Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System (ALZLIGHT Pilot)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04574921 |
|
Recruitment Status :
Completed
First Posted : October 5, 2020
Last Update Posted : December 13, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Induction of neural oscillations by flickering light is a well established method used for diagnostic of various neural diseases.
Recent studies in mice have shown promising results indicating that induction of gamma oscillation at 40 Hz leads to a reduction in amyloid-β and tau in mice models of Alzheimer's disease. This study will use flickering light to induce 40 Hz gamma oscillation as the previously mentioned studies.
In the study subject will be exposed to invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) for 1 hour each day. The sham setting is a high quality sham intervention as subjects will be blinded to the setting, both appears as white light.
As this is the first trial, the focus will be on 1) safety of the intervention 2) feasibility of the proposed intervention time and method 3) indication of efficacy.
In stage 1 of the trial 4 age-matched subjects with no Alzheimer's disease will be recruited and be exposed for 1 week. In stage 2 10 patients with Alzheimer's disease will be recruited and exposed for 6 consecutive weeks.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alzheimer Disease | Other: Light Therapy System (LTS): Active setting Other: Light Therapy System (LTS): Sham setting | Not Applicable |
Induction of neural oscillations by flickering light is a well established method used for diagnostic of various neural diseases (5,6).
Recent studies in mice have shown promising results indicating that induction of gamma oscillation at 40 Hz leads to a reduction in amyloid-β an tau in mice models of Alzheimer's disease (1-4). This study will use flickering light to induce 40 Hz gamma oscillation as the previously mentioned studies.
This study will utilize a novel way of masking the light by alternating the spectral composition of a white light, rendering the flicker invisible to the conscience perception while still entraining 40 Hz oscillations in the brain.
In the study subject will be exposed to invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) for 1 hour each day. The sham setting is a high quality sham intervention as subjects will be blinded to the setting, both appears as white light.
As this is the first trial, the focus will be on 1) safety of the intervention 2) feasibility of the proposed intervention time and method 3) indication of efficacy.
In stage 1 of the trial 4 age-matched subjects with no Alzheimer's disease will be recruited and be exposed for 1 week. In stage 2 10 patients with Alzheimer's disease will be recruited and exposed for 6 consecutive weeks. Following the 6 weeks of intervention the subject will have 6 weeks of no intevention and assesed agian.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 16 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Other |
| Official Title: | ALZLIGHT Pilot: Study on Safety, Feasibility and Neural Activation of Non-Invasive Light Therapy System |
| Actual Study Start Date : | October 1, 2020 |
| Actual Primary Completion Date : | July 12, 2022 |
| Actual Study Completion Date : | July 12, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Active
Exposure to LTS device set to 40 Hz invisible spectral flicker for 1 hour a day for consecutive days
|
Other: Light Therapy System (LTS): Active setting
Exposure for 1 hour á day for consecutive days. |
|
Sham Comparator: Sham
Exposure to LTS device set to continues color matched white light for 1 hour a day for consecutive days
|
Other: Light Therapy System (LTS): Sham setting
Exposure for 1 hour á day for consecutive days. |
- Stage I: Feasibility / Compliance assesment [ Time Frame: After 1 week of intervention ]• The compliance of the LTS intervention will be measured by the amount of time (in minutes) of device use per day.
- Stage I: Usability Assessment: [ Time Frame: After 1 week of intervention ]• Usability report on use of device during intervention in the subject's home based on device speciffic questionnaire / structured interviews
- Stage I: Safety Assessment. Evaluation of Adverse Events related to the LTS intervention. [ Time Frame: After 1 week of intervention ]• Safety assessment will be done by collection of all types of adverse events and categorization into severity and relationship to LTS treatment.
- Stage II: Feasibility / Compliance assesment [ Time Frame: After 6 weeks of intervention and subsequent 6 weeks of no intervention ]• The compliance of the LTS intervention will be measured by the amount of time (in minutes) of device use per day.
- Stage II: Safety Assessment. Evaluation of Adverse Events related to the LTS intervention. [ Time Frame: After 6 weeks of intervention and subsequent 6 weeks of no intervention ]• Device- and procedure-related adverse events (DR/PR-AEs) including serious AEs (SAEs) occurring at any time during the trial
- Stage II: Induction of gamma ocsillations [ Time Frame: Changes from baseline to 6 and 12 weeks ]• The effect of the LTS intervention will be measured by the amount of 40 Hz SSVEP response during treatment
- Stage II: Connectivity meassures in resting-state functional MRI [ Time Frame: Changes from baseline to 6 and 12 weeks ]• rs-fMRI Connectivity: Change from baseline in correlations between cortical regions at 6 weeks
- Stage II: Connectivity meassures in EEG [ Time Frame: Changes from baseline to 6 and 12 weeks ]• EEG Connectivity: Change from baseline in correlations between cortical regions at 6 weeks
- Stage II: Changes in cognition: [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Changes in cognition meassured by the ADAS Cog Plus EF & FA neuropsychological test. Score from 0 to 200
- Stage II: Changes in cognition: [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Changes in cognition meassured by the Trailmaking A&B score from 0 to 1200 seconds
- Stage II: Changes MR spectroscopy [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Chance from baseline in brain metabolism at 6 weeks
- Stage II: Changes MR Perfusion [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Chance from baseline in perfusion meassured by Arterial Spin Labelling at 6 weeks
- Stage II: Changes MR volumemetry [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Chance from baseline in structural volume of neural structures at 6 weeks
- Stage II: Changes in Sleep Quality: [ Time Frame: Changes from baseline to 6 and 12 weeks ]• Actigraphy: To assess changes in sleep patterns
- Stage II: EEG spectral features: [ Time Frame: Changes from baseline to 6 and 12 weeks ]• rs-EEG fourier power: To assess changes in spectral features
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 55 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Adult competent persons able to understand the nature of the study and give written informed consent.
- Stage I: Healthy elderly subject.
- Stage II: Diagnosed with probable mild to moderate AD based on NIA-AA diagnostic criteria.
- Age >55 years and <80 years. Females must be post-menopausal.
- Fluent in Danish
- > 8 year of normal school education
- Pass a colour-blindness test (Ishihara colour test)
- Have visual and auditory capabilities, and language skills necessary for neuropsychological testing.
- Furthermore, subjects must have a person, hereafter named designated caregiver, who is available to the participant and can provide the necessary assistance with using the LTS device and Actigraph wearable at home and can assist with clinic visits and other practical issues.
Exclusion Criteria:
- Profound visual impairment provided correction with spectacles, if needed.
- Significant abnormalities related to important parts of the brain e.g. the visual system, pre-frontal cortex or hippocampus, or relevant lesions detected by MRI.
- Prior history of significant diseases related to the visual system or the brain.
- Medication Any patient using antiepileptic drugs, neuromodulating drugs or high dose of sedatives will be excluded.
- Prior history of substance abuse within the past 2 years.
- Any significant systemic illness or unstable medical condition, which could lead to difficulty complying with the protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04574921
| Denmark | |
| Zealand University DK34197393 | |
| Roskilde, Region Zealand, Denmark, 4000 | |
Publications:
| Responsible Party: | Zealand University Hospital |
| ClinicalTrials.gov Identifier: | NCT04574921 |
| Other Study ID Numbers: |
REG-085-2020 |
| First Posted: | October 5, 2020 Key Record Dates |
| Last Update Posted: | December 13, 2022 |
| Last Verified: | December 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Gamma entrainment 40 Hz Invisible Spectral Flicker LED |
Light Therapy Brain stimulation Gamma oscillations Gamma induction |
|
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders |